Cyclomedica Australia

Cyclopharm is an Australian-based radiopharmaceutical company that develops and manufactures specialized medical equipment and consumables for diagnostic imaging. The company's flagship technology, Technegas, is an ultra-fine carbon nano-particle labeled with Technetium-99m, used in functional lung ventilation imaging to diagnose conditions like pulmonary embolism. Technegas is recognized globally for its superior imaging quality compared to traditional aerosols, particularly in patients with underlying obstructive airway disease. Having secured FDA approval in late 2023, the company is currently focused on its commercial rollout in the United States. Beyond its primary indication, Cyclopharm is expanding the use of Technegas into new therapeutic areas, including the management of COPD, asthma, and long COVID.